SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Microcap Potential Homeruns--Credible, and Reporting
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ted M who wrote (497)2/16/2010 1:17:40 AM
From: caly  Read Replies (1) of 1056
 
marketwatch.com

For the full year 2010, Senomyx expects:

-- Total revenues of $20 million to $24 million

-- Total expenses of $42 million to $44 million, of which $5 million to $6 million is non-cash, stock-based compensation expense

-- Net loss of $18 million to $21 million

-- Basic and diluted net loss of $0.57 to $0.67 per share

-- Net cash used in operating activities between $14 million and $16 million

As far as GNVC goes, I read an article in a local business journal about them not long ago and remembered them from years ago as supposedly having promising things in the pipeline. I did a little more reading, and there's a lot of very optimistic people people out there, so I decided to roll the dice...literally, because all these pharmas seem to be total crapshoots. I've done well with some just on a hunch, though, and it keeps me coming back.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News